BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1235 related articles for article (PubMed ID: 27059391)

  • 21. C9orf72 isoforms in Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration.
    Xiao S; MacNair L; McLean J; McGoldrick P; McKeever P; Soleimani S; Keith J; Zinman L; Rogaeva E; Robertson J
    Brain Res; 2016 Sep; 1647():43-49. PubMed ID: 27134035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. All in the Family: Repeats and ALS/FTD.
    Pattamatta A; Cleary JD; Ranum LPW
    Trends Neurosci; 2018 May; 41(5):247-250. PubMed ID: 29703376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insights into disease mechanisms and potential therapeutics for C9orf72-related amyotrophic lateral sclerosis/frontotemporal dementia.
    Gagliardi D; Costamagna G; Taiana M; Andreoli L; Biella F; Bersani M; Bresolin N; Comi GP; Corti S
    Ageing Res Rev; 2020 Dec; 64():101172. PubMed ID: 32971256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of C9orf72 repeat expansions in patients with amyotrophic lateral sclerosis and frontotemporal dementia in mainland China.
    Jiao B; Tang B; Liu X; Yan X; Zhou L; Yang Y; Wang J; Xia K; Shen L
    Neurobiol Aging; 2014 Apr; 35(4):936.e19-22. PubMed ID: 24269022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How villains are made: The translation of dipeptide repeat proteins in C9ORF72-ALS/FTD.
    Van't Spijker HM; Almeida S
    Gene; 2023 Mar; 858():147167. PubMed ID: 36621656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS.
    Gendron TF; Bieniek KF; Zhang YJ; Jansen-West K; Ash PE; Caulfield T; Daughrity L; Dunmore JH; Castanedes-Casey M; Chew J; Cosio DM; van Blitterswijk M; Lee WC; Rademakers R; Boylan KB; Dickson DW; Petrucelli L
    Acta Neuropathol; 2013 Dec; 126(6):829-44. PubMed ID: 24129584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD.
    Starr A; Sattler R
    Brain Res; 2018 Aug; 1693(Pt A):98-108. PubMed ID: 29453960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases.
    Riboldi G; Zanetta C; Ranieri M; Nizzardo M; Simone C; Magri F; Bresolin N; Comi GP; Corti S
    Mol Neurobiol; 2014 Dec; 50(3):721-32. PubMed ID: 24809691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ADAR2 mislocalization and widespread RNA editing aberrations in C9orf72-mediated ALS/FTD.
    Moore S; Alsop E; Lorenzini I; Starr A; Rabichow BE; Mendez E; Levy JL; Burciu C; Reiman R; Chew J; Belzil VV; W Dickson D; Robertson J; Staats KA; Ichida JK; Petrucelli L; Van Keuren-Jensen K; Sattler R
    Acta Neuropathol; 2019 Jul; 138(1):49-65. PubMed ID: 30945056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD.
    Liu Y; Pattamatta A; Zu T; Reid T; Bardhi O; Borchelt DR; Yachnis AT; Ranum LP
    Neuron; 2016 May; 90(3):521-34. PubMed ID: 27112499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retention of hexanucleotide repeat-containing intron in C9orf72 mRNA: implications for the pathogenesis of ALS/FTD.
    Niblock M; Smith BN; Lee YB; Sardone V; Topp S; Troakes C; Al-Sarraj S; Leblond CS; Dion PA; Rouleau GA; Shaw CE; Gallo JM
    Acta Neuropathol Commun; 2016 Feb; 4():18. PubMed ID: 26916632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the dipeptide repeat protein in the molecular pathogenesis of c9FTD/ALS.
    Yamakawa M; Ito D; Honda T; Kubo K; Noda M; Nakajima K; Suzuki N
    Hum Mol Genet; 2015 Mar; 24(6):1630-45. PubMed ID: 25398948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcription elongation factor AFF2/FMR2 regulates expression of expanded GGGGCC repeat-containing C9ORF72 allele in ALS/FTD.
    Yuva-Aydemir Y; Almeida S; Krishnan G; Gendron TF; Gao FB
    Nat Commun; 2019 Nov; 10(1):5466. PubMed ID: 31784536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenic Mechanisms and Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis/Frontotemporal Dementia.
    Jiang J; Ravits J
    Neurotherapeutics; 2019 Oct; 16(4):1115-1132. PubMed ID: 31667754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions.
    Simón-Sánchez J; Dopper EG; Cohn-Hokke PE; Hukema RK; Nicolaou N; Seelaar H; de Graaf JR; de Koning I; van Schoor NM; Deeg DJ; Smits M; Raaphorst J; van den Berg LH; Schelhaas HJ; De Die-Smulders CE; Majoor-Krakauer D; Rozemuller AJ; Willemsen R; Pijnenburg YA; Heutink P; van Swieten JC
    Brain; 2012 Mar; 135(Pt 3):723-35. PubMed ID: 22300876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype.
    Rutherford NJ; Heckman MG; Dejesus-Hernandez M; Baker MC; Soto-Ortolaza AI; Rayaprolu S; Stewart H; Finger E; Volkening K; Seeley WW; Hatanpaa KJ; Lomen-Hoerth C; Kertesz A; Bigio EH; Lippa C; Knopman DS; Kretzschmar HA; Neumann M; Caselli RJ; White CL; Mackenzie IR; Petersen RC; Strong MJ; Miller BL; Boeve BF; Uitti RJ; Boylan KB; Wszolek ZK; Graff-Radford NR; Dickson DW; Ross OA; Rademakers R
    Neurobiol Aging; 2012 Dec; 33(12):2950.e5-7. PubMed ID: 22840558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced autophagy upon C9ORF72 loss synergizes with dipeptide repeat protein toxicity in G4C2 repeat expansion disorders.
    Boivin M; Pfister V; Gaucherot A; Ruffenach F; Negroni L; Sellier C; Charlet-Berguerand N
    EMBO J; 2020 Feb; 39(4):e100574. PubMed ID: 31930538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Divergence, Convergence, and Therapeutic Implications: A Cell Biology Perspective of C9ORF72-ALS/FTD.
    Tang X; Toro A; T G S; Gao J; Chalk J; Oskarsson B; Zhang K
    Mol Neurodegener; 2020 Jun; 15(1):34. PubMed ID: 32513219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis.
    Rohrer JD; Isaacs AM; Mizielinska S; Mead S; Lashley T; Wray S; Sidle K; Fratta P; Orrell RW; Hardy J; Holton J; Revesz T; Rossor MN; Warren JD
    Lancet Neurol; 2015 Mar; 14(3):291-301. PubMed ID: 25638642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs.
    Jiang J; Zhu Q; Gendron TF; Saberi S; McAlonis-Downes M; Seelman A; Stauffer JE; Jafar-Nejad P; Drenner K; Schulte D; Chun S; Sun S; Ling SC; Myers B; Engelhardt J; Katz M; Baughn M; Platoshyn O; Marsala M; Watt A; Heyser CJ; Ard MC; De Muynck L; Daughrity LM; Swing DA; Tessarollo L; Jung CJ; Delpoux A; Utzschneider DT; Hedrick SM; de Jong PJ; Edbauer D; Van Damme P; Petrucelli L; Shaw CE; Bennett CF; Da Cruz S; Ravits J; Rigo F; Cleveland DW; Lagier-Tourenne C
    Neuron; 2016 May; 90(3):535-50. PubMed ID: 27112497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.